Vmbook Online ordering

Rubber Plastics

I have gathered some general information about the public company "Cocrystal Pharma, Inc." (NASDAQ: COCP) for you. Please note that while I strive to provide accurate information, it is always best to directly consult the latest financial documents and press releases from the company for the most up-to-date and detailed data.

Company Name: Cocrystal Pharma, Inc.

Stock Symbol: COCP (formerly CXDC)

Exchange: NASDAQ

1. Overview:

Cocrystal Pharma, Inc. is a clinical-stage biotechnology company focused on discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses. The company utilizes its proprietary structure-based drug design technology to create potential next-generation antiviral drugs. Their primary focus has been on influenza, but they have also conducted exploratory work on coronaviruses, including SARS-CoV-2.

2. Financials:

For the fiscal year ending March 31, 2022 (FY2022):

- Revenue: $0.19 million (YOY increase of 34.8%)

- Net Loss: $(11.29) million (YOY decrease of 32.6%)

- Cash and Cash Equivalents: $3.99 million

3. Recent Earnings & Growth:

Cocrystal Pharma, Inc. has not reported earnings for FY2022 yet, and their most recent report was for FY2021. Based on that report, the company has been incurring losses and has not yet generated positive net income. However, they have been focusing on research and development, with an extensive intellectual property portfolio to support their drug development efforts.

Please note that investing in the stock market always carries risks, and it is important to thoroughly research a company and its financials before making any investment decisions. This information is only a starting point and should not be used as the sole basis for making an investment decision. Always consult a financial advisor or conduct your own research before investing.